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Abstract
Many genetic causes of developmental delay and/or intellectual disability (DD/ID) are extremely rare, and robust discovery 
of these requires both large-scale DNA sequencing and data sharing. Here we describe a GeneMatcher collaboration which 
led to a cohort of 13 affected individuals harboring protein-altering variants, 11 of which are de novo, in MED13; the only 
inherited variant was transmitted to an affected child from an affected mother. All patients had intellectual disability and/or 
developmental delays, including speech delays or disorders. Other features that were reported in two or more patients include 
autism spectrum disorder, attention deficit hyperactivity disorder, optic nerve abnormalities, Duane anomaly, hypotonia, 
mild congenital heart abnormalities, and dysmorphisms. Six affected individuals had mutations that are predicted to truncate 
the MED13 protein, six had missense mutations, and one had an in-frame-deletion of one amino acid. Out of the seven non-
truncating mutations, six clustered in two specific locations of the MED13 protein: an N-terminal and C-terminal region. 
The four N-terminal clustering mutations affect two adjacent amino acids that are known to be involved in MED13 ubiqui-
tination and degradation, p.Thr326 and p.Pro327. MED13 is a component of the CDK8-kinase module that can reversibly 
bind Mediator, a multi-protein complex that is required for Polymerase II transcription initiation. Mutations in several other 
genes encoding subunits of Mediator have been previously shown to associate with DD/ID, including MED13L, a paralog 
of MED13. Thus, our findings add MED13 to the group of CDK8-kinase module-associated disease genes.
Introduction
The introduction of next-generation sequencing techniques 
has rapidly improved the identification of genes that associ-
ate with rare disease. Although developmental delay (DD) 
and intellectual disability (ID) are relatively common (Boat 
and Wu 2015; Boyle et al. 2011), there is extreme genetic 
heterogeneity among affected patients and a large fraction 
of patients with DD/ID remain refractory to diagnosis (Vis-
sers et al. 2016). In unsolved cases, the understanding of 
gene–disease relationships has greatly benefited from col-
laboration between clinical genetics teams (Sobreira et al. 
2015). In fact, many recently discovered DD/ID genes have 
come from “matchmaking” (Au et al. 2015; Harms et al. 
2017; Kernohan et al. 2017), where websites such as Gen-
eMatcher (Sobreira et al. 2015) facilitate the comparison 
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of patients with rare genotypes and phenotypes across the 
world.
Here we present the results of a collaboration facilitated 
by GeneMatcher (Sobreira et  al. 2015) in which multi-
ple clinical and research groups independently identified 
individuals with DD/ID and related phenotypes with rare 
protein-altering variation in MED13. This genotype-driven 
approach enabled us to characterize the phenotypes and 
mutational spectrum of a cohort of 13 patients, each with a 
likely pathogenic variant in MED13.
Although MED13 has not been previously linked to a dis-
order, it is a paralog of MED13L, mutations of which have 
been found to cause ID, speech impairment and heart defects 
(Adegbola et al. 2015; Muncke et al. 2003; van Haelst et al. 
2015). The gene products MED13 and MED13L are mutu-
ally exclusive components of the reversible CDK8-module 
of the Mediator complex, a multi-protein complex that is 
required for the expression of all protein-coding genes (Con-
away et al. 2005; Malik and Roeder 2005). In this study, we 
show that variants in MED13 are also associated with a neu-
rodevelopmental disorder, and delineate the corresponding 
phenotypic features and mutational spectrum.
Materials and methods
Informed consent
Informed consent to publish de-identified data was obtained 
from all patients, either as part of the diagnostic workflow or 
as part of a research study (Bowling et al. 2017). Informed 
consent to publish clinical photographs was also obtained 
when applicable. Informed consent matched the local ethi-
cal guidelines.
Exome/genome sequencing
In patients A, B, D, E, F, G, I, K, L and M, whole exome 
sequencing and variant filtering were performed as previ-
ously published (de Ligt et al. 2012; Deciphering Develop-
mental Disorders 2015; Neveling et al. 2013; Sollis et al. 
2017; Tanaka et al. 2015). In patient C, targeted Sanger 
sequencing was performed to confirm the presence of the 
MED13 variant (L131*) that was first identified in patient 
B. For patient H, whole genome sequencing was performed 
using Illumina’s HiSeq X ten platform. Sequencing reads 
were mapped against the hs37d5 reference using GATK. 
Variants were called using GATK’s Haplotype Caller. Vari-
ants were filtered using frequencies from the ExAC and 
gnomAD databases (mean allele frequency < 0.003) and 
for conservation using PhastCons (> 0.5) and PhyloP (> 4). 
For patient J, whole genome sequencing, variant prioritiza-
tion, and Sanger validation were performed as previously 
described (Bowling et  al. 2017). In each patient, the 
observed MED13 mutation was considered to be the most 
likely contributor to the phenotype, and no additional patho-
genic or likely pathogenic variants were found.
Three‑dimensional modeling
Protein modeling was performed as previously described 
(Prokop et al. 2017). Modeling of MED13 interacting with 
FBXW7 was performed using PDB 2OVQ, replacing mol-
ecule C with the MED13 amino acids 321–330. Binding 
energy was calculated following each patient variant inser-
tion and energy minimization using AMBER14 force field 
(http://amber md.org/) in YASARA.
RNA isolation
2.5 mL of blood was collected in PAXgene RNA tubes 
(PreAnalytiX #762165) according to the manufacturer’s 
instructions and stored short-term at − 20 °C. RNA was iso-
lated using a PAX gene Blood RNA Kit (Qiagen #762164) 
according to the manufacturer’s instructions. Isolated RNA 
was quantified by Qubit® (Thermo Fisher #Q32855).
cDNA synthesis
First strand synthesis of cDNA was performed from 150 ng 
of RNA isolated from blood using Superscript™ III (Thermo 
Fisher #18080044) according to manufacturer’s instructions 
using random primers (Invitrogen #48190011) for +/− RT 
reactions. The products were diluted 1:10 in water before 
use in qPCR reactions.
qPCR
qPCR was performed according to manufacturer’s protocols 
using Taqman gene expression master mix (ThermoFisher 
#4369016) and FAM-MGB Taqman probes directed against 
MED13 (ThermoFisher Hs01080701_m1 catalog #4331182) 
and GAPDH (ThermoFisher #4352934E). qPCR reactions 
were carried out in a QuantStudio 6 Flex Real-Time PCR 
system (Applied Biosystems) using 40 cycles of amplifi-
cation. Raw  CT values were obtained, normalized first to 
the GAPDH loading control, and then to the proband. We 
tested an additional loading control [AGPAT-data not shown 
(ThermoFisher Hs00965850_g1; catalog #4331182)], but 
the data were like those normalized to GAPDH.
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Sanger sequencing
cDNA template was amplified using primers to the region 
of interest: 5′-CGA GGC TCT TAT GGA ACT GAT GAA 
TC-3′ (forward) and 5′-GAT CCA TCG TGC TTT CAG ACA 
CAT C-3′ (reverse). No amplification was observed in the 
no RT condition. PCR conditions were: 500 nM prim-
ers, 3% DMSO, 1x Phusion HF (NEB #M0531L), 0.5 µL 
cDNA template, and cycling at (98 °C, 30 s), (98 °C, 10 s; 
60 °C, 30 s; 72 °C, 45 s)x35, (72 °C, 7 m), (4 °C, ∞). The 
additional reverse primer 5′-AAA TGC TTC ATT GTT ACC 
GTC AGC T-3′ and the additional forward primers 5′-TCC 
AAA AGA AAC GAT GTG AGT ATG CAG-3′, 5′-CTC TCT 
TCA GCC AGT TCT TCA GGA T-3′, 5′-ACA ATT TCA TAA 
AAT GGC TGG CCG A-3′, 5′-CGA GGC TCT TAT GGA ACT 
GAT GAA TC-3′, 5′-GTG CTT TCT CCA TTT GCT CTT CCT 
T-3′ were used for sequencing, along with the primers used 
for amplification from cDNA. Chromatograms were quan-
tified using ab1PeakReporter (Thermo Fisher).
Western Blot
Whole blood was collected using cell processing tubes 
(BD #362760), isolated according to the manufacturer’s 
instructions, and stored in liquid nitrogen in CTS™ 
Synth-a-Freeze® Medium (Thermo Fisher # A13713-01) 
until use. As a control for antibody specificity, MED13 
was knocked down in neural precursor cells (clone BC1, 
MTI-GlobalStem #GSC-4311) by generating stable lines 
using puromycin selection expressing shRNA against 
MED13 (Sigma Aldrich # SHCLNG-NM_005121; 
TRCN0000234904) compared to a GFP shRNA control 
in the same vector (Addgene # 30323). Cell pellets were 
processed using the NE-PER™ (Thermo Fisher #78833) 
nuclear and cytoplasmic extraction kit according to the 
manufacturer’s instructions, and nuclear extracts were 
used for the blot shown (whole cell extracts, even at very 
high concentrations, did not produce sufficient signal). 
60 µg of protein was loaded for patient blood samples, 
and 15 µg of protein was loaded for neural precursor cell 
samples. Blots were blocked for 1 h at room temperature in 
LICOR blocking buffer (LICOR #927-40000), then blots 
were probed (with washes in PBS-T (0.05% Tween-20) 
and a secondary probe for 1 h after each primary probe) 
with 1:250 rabbit anti-MED13 (Bethyl #A301-277A) for 
3 days at 4 °C, 1:1,000 mouse anti-HDAC2 (clone 3F3, 
SCBT #sc-81599) overnight at 4 °C as a loading control, 
and 1:1000 rabbit anti-HSP90 (abcam #ab115660) over-
night at 4 °C as an additional loading control. Secondary 
probes were used at 1:20,000 (LICOR #926-32211 and 
#926-68070). Three other primary antibodies were tested 
for MED13, but did not show sufficient signal to detect 
MED13 in blood despite detecting MED13 in neural pre-
cursor nuclear lysates: Bethyl #278A, Abcam #ab49468, 
and Abcam #ab76923 (data not shown).
Statistical enrichment of MED13 variants in DD/ID 
cohorts
We compared the frequency of observed de novo MED13 
variation identified in two large sequencing cohorts to the 
expected frequency of variation in MED13 based on its gene 
specific mutation rate (Samocha et al. 2014) using an Exact 
Poisson Test in R (R Core Team. R: A language and envi-
ronment for statistical computing (http://www.r-proje ct.org). 
Vienna).
Results
Phenotypes
We collected detailed clinical information of 13 patients 
with rare, protein-altering MED13 variants. Eleven variants 
were confirmed to be de novo, and one patient (patient B) 
inherited the variant from her mother who is also affected 
(patient C). Phenotypic data summarizing the spectrum of 
features of this cohort of 13 patients are shown in Table 1.
All patients had developmental delays with varying sever-
ity and course. In the patients that underwent formal intel-
ligence testing, total IQ levels varied from 85 (lower range 
of normal IQ) to an IQ between 35 and 50 (moderate ID). 
Five patients had an Autism Spectrum Disorder (ASD), and 
three patients were diagnosed with Attention Deficit Hyper-
activity Disorder (ADHD). All patients had speech delays 
and/or disorders, with delayed milestones in speech and lan-
guage development. While several patients had expressive 
and receptive language problems, in the majority of patients, 
speech production was significantly more impaired than lan-
guage comprehension. Three patients (patient A, K and M) 
showed characteristics of speech apraxia, a developmental 
speech disorder in which affected individuals have difficul-
ties accurately programming the motor sequences required 
to produce fluent speech. Patient A had a mild ID, but 
showed speech apraxia with a mixed receptive and expres-
sive language disorder, and limited verbal expression at the 
age of 8 years. Patient M had a non-verbal IQ of 70 with a 
severe speech/language disorder. Her expressive speech was 
severely affected, with signs of speech apraxia. At the age of 
8 years she only used single words and very short sentences. 
Patient K developed some speech capabilities, but showed 
regression at the age of 13 months and has since remained 
non-verbal.
Seven of 13 patients showed delays in motor develop-
ment, most of which affected at least the gross motor skills 
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(6 of 7), although one patient was reported to have only 
fine motor delays. Three patients had hypotonia (patient E, 
F and G). One patient (patient H) developed severe drug-
resistant myoclonic-atonic epilepsy at 4 years of age with 
generalized clonic, myoclonic, atonic, tonic and atypical 
absence seizures. MRI screening of this patient showed a 
small abnormality in the left occipital lobe of his brain that 
did not correspond to the electrophysiological onset or the 
semiology of his seizures. In other patients, MRI scans were 
not performed or showed no clear abnormalities, except for 
mild frontal atrophy in patient M.
Eight patients (62%) presented with eye or vision abnor-
malities. Two patients (patients L and M) presented with 
Duane anomaly, a congenital type of strabismus that is char-
acterized by non-progressive horizontal ophtalmoplegia and 
retraction of the globe with attempted adduction, together 
with narrowing of the palpebral fissure (Andrews et al. 
1993). One patient (patient G) had strabismus, two patients 
had astigmatism (patient A and I), and one patient (patient 
E) had congenital nystagmus. While only one patient (patient 
D) had a visual impairment, three patients had optic nerve 
abnormalities: pale optic nerves in patient D, papilledema 
in patient G, and in patient E outer retinal atrophy temporal 
to both optic discs was reported with relatively small optic 
nerves on a MRI-scan.
Several other interesting phenotypes were observed in at 
least two patients in the cohort. Four patients presented with 
chronic obstipation (patients C, E, G and M). Two patients 
had conductive hearing loss (patients F and L). Two patients 
had congenital heart abnormalities: a mildly dilated aortic 
root and pulmonary artery (both improving over time) in 
patient F, and a subaortic stenosis in patient J. Two patients 
were reported to have chronic sleep issues (patient J and K).
Overlapping facial characteristics were reported, includ-
ing widely spaced eyes with narrow palpebral fissures and 
peri-orbital fullness, a broad and high nasal bridge, full nasal 
tip, synophrys, a flat philtrum and a wide mouth with thin 
upper lip (Fig. 1).
Variants and predicted consequences
The MED13 transcript (NM_005121.2) encodes a large pro-
tein consisting of 2174 amino acids (NP_005112.2). The 
Pfam database characterizes two domains within the MED13 
protein: an N-terminal domain (aa 11–383) and a C-terminal 
domain (aa 1640–2163), as shown in Fig. 2a. Analysis of 
conservation across the length of the protein indicates sev-
eral highly conserved residues that lie between these two 
domains (Fig. 2b).
All 12 unique variants found in our patients are absent 
from the gnomAD database (Lek et al. 2016) and TOPMED 
Bravo database (https ://bravo .sph.umich .edu/freez e3a/
hg19/) and are predicted to be highly deleterious by CADD 
v1.3 (Kircher et al. 2014), with scores ranging from 20.5 
to 41 (Table 1). Six patients had five unique variants that 
are predicted to be truncating: three nonsense mutations 
(p.Leu131* in Patients B and C, p.Leu582* in Patient I and 
p.Arg1400* in Patient J) and two frameshift variants lead-
ing to a premature stop codon (p.Pro42Leufs*6 in patient A 
and p.Thr1496Metfs*11 in Patient K). The remaining vari-
ants include six missense variants and a single amino acid 
deletion. These seven variants form two apparent clusters: 
one in the N-terminal conserved phosphodegron domain 
and the other in the C-terminal domain (Fig. 2a). These 
seven variants were all found to lie within motifs that are 
highly conserved between MED13 and MED13L (Fig. 2b) 
and affect sites under high codon selection (Fig. 2c). These 
missense variants and the in-frame deletion are each located 
on surface-exposed sites within a three-dimensional model 
of the MED13 protein (Fig. 3). The four mutations that 
cluster in the N-terminal domain affect two adjacent amino 
acids (p.Thr326 and p.Pro327) that are known to be part 
of a conserved phosphodegron that is required for binding 
with SCF-Fbw7 ubiquitin ligase for degradation (Davis et al. 
2013). Using interaction data from Davis et al. and PDB 
structure 2OVQ, which has Fbw7 interacting with a similar 
motif as MED13, we modeled this interaction for MED13 
followed by insertion of each variant and calculation of 
binding energy. All four variants (p.Thr326Ile, p.Thr326del, 
p.Pro327Ser, p.Pro327Gln) are predicted to alter the phos-
phorylation and Fbw7 interaction with drastic decreases in 
binding energy to Fbw7 (Supplementary Fig. 1). The two 
missense changes clustering in the C-terminal portion of 
the protein (p.Gln2060Lys and p.Ala2064Val; in patients L 
and M, respectively) were also studied in more detail. One 
of the changes (p.Ala2064Val) is predicted to be structure-
altering through increasing hydrophobic collapse, second-
ary structure formation, and increasing aliphatic index of a 
surface exposed linear motif. This results in a decrease of 
the regions linear interacting peptide potential that is highly 
conserved and likely functional (Supplementary Fig. 2). The 
remaining missense variant (p.Pro540Thr in Patient H) lies 
within a highly conserved linear motif centered near amino 
acid 538 (Fig. 2b); it results in the formation of a high prob-
ability Casein Kinase 1 phosphorylation motif, which could 
lead to additional interaction with proteins containing fork-
head-associated domains when analyzed through the ELM 
database (Dinkel et al. 2016) (Fig. 3).
Effects of truncating MED13 mutation on transcript 
and protein levels
As truncating mutations often lead to nonsense-medi-
ated decay and haploinsufficiency, we aimed to examine 
the effects of a truncating MED13 mutation on levels of 
MED13 transcript and MED13 protein. We performed 
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RT-PCR on cDNA transcribed from RNA of patient J, who 
was heterozygous for a nonsense mutation (c.4198C > T; 
p.Arg1400*). We compared the MED13 transcript level of 
the patient to her biological parents and two healthy con-
trols (Fig. 4a). No differences in MED13 transcript levels 
were detectable between the affected patient and the unaf-
fected parents or controls (One-way ANOVA p = 0.5913). 
Sanger sequencing of cDNA amplicons from the child 
demonstrated the presence of the aberrant transcript in 
the child (Fig. 4b), at ~ 70% levels relative to the normal 
transcript (Fig. 4c). To assess the effect of the nonsense 
mutation on protein levels, a western blot was performed 
on nuclear extracts from mononuclear blood cells of the 
patient and controls (Fig. 4d). While full-length MED13 
protein was present in the patient (and in the controls), no 
truncated MED13 protein product could be detected. The 
MED13 protein level of the patient was not clearly differ-
ent compared with the MED13 protein level of the father.
Enrichment of de novo MED13 variants in DD/ID 
cohorts
We quantified the extent of enrichment of de novo variants 
in MED13 within DD/ID-affected probands. We used only 
the two largest cohorts considered within this study, each 
of which yielded at least two de novo MED13 variants. 
Five patients described here (A, E, F, I, and K) come from 
a cohort of 11,149 affected individuals, and two patients, 
one of which is described here (patient L), were identified 
within the Deciphering Developmental Disorders (DDD) 
study of 4293 trios (Deciphering Developmental Disor-
ders 2017). Both studies suggest a rate close to 1 de novo 
variant affecting MED13 per ~ 2200 DD/ID-affected indi-
viduals. When comparing the number of observed de novo 
mutations in MED13 to the expected number based on the 
gene specific mutation rate of MED13 for missense, splice-
site, nonsense and frameshift mutations [6.237 × 10−5 per 
chromosome (Samocha et al. 2014)], we find evidence for 
a significant enrichment among DD/ID-affected individu-
als (7 variants in 30,884 alleles; p = 0.00371).
Fig. 1  Facial phenotypes of seven individuals with a MED13 variant. Overlapping facial characteristics include peri-orbital fullness, narrow pal-
pebral fissures, a broad and high nasal bridge, full nasal tip, synophrys, flat philtrum, wide mouth and a thin upper lip
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Discussion
By molecular and clinical characterization of a cohort 
of 13 patients with variants in MED13, we here provide 
evidence for a new neurodevelopmental disorder. This 
MED13-associated syndrome is characterized by DD/
ID with speech delay and/or speech disorders. Addition-
ally a broad spectrum of other common features is seen, 
including ASD, ADHD, various eye abnormalities and 
mild facial dysmorphisms. Based on the phenotypes of 
patients presented here, we do not yet see a clear geno-
type-phenotype correlation between type and location of 
Fig. 2  Analysis of mutations: location, conservation and codon usage 
of variant sites. a Identified mutations are shown within a linear rep-
resentation of the MED13 protein, consisting of 2174 amino acids. 
Missense mutations and the in-frame deletion are shown in blue, 
and nonsense and frameshift mutations in green. Six of the seven 
non-truncating mutations in our MED13 cohort cluster in two small 
regions within the N-terminal and C-terminal domains of the MED13 
protein. Affected amino acids p.Thr326 and p.Pro327 and are part of 
a conserved phosphodegron (CPD), which is shown in orange. Two 
LxxLL nuclear receptor-binding motifs are also noted. b Analysis of 
conservation throughout the protein was performed using amino acid 
selection scores as previously published (Prokop et  al. 2017), using 
a 21 codon sliding window for both MED13 and MED13L aligned 
such that the most selected motifs of a protein are identified as peaks. 
The center of each highly conserved linear motif is labeled and those 
containing variants described in this paper are boxed. c Codon usage 
throughout evolution for the locations of all missense mutations and 
the in-frame deletion. All five sites are under high selection with 
multiple synonymous (Syn, gray) amino acids in 352 open reading 
frames (ORFs) of MED13 and MED13L with only a single nonsyn-
onymous (Nonsyn, red) change. Numbers indicate instances where 
ORFs in other species deviate from the conserved codon usage. Of 
note, for three locations (326, 327 and 540) the codon used differs 
between MED13 and MED13L with the amino acid conserved. In 
these cases, numbers indicate where ORFs in other species deviate 
from conserved codon usage in their respective ortholog
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the mutations and severity of clinical features. However, it 
is notable that the two patients with Duane anomaly have a 
missense mutation in a similar location in the C-terminal 
domain of the MED13 protein, and that the optic nerve 
abnormalities are reported in patients with mutations 
affecting residues p.Thr326 or p.Pro327 only.
MED13 is a component of the CDK8-kinase module, 
which can reversibly bind the Mediator complex. Media-
tor is a multi-protein complex that is required for assem-
bly and stabilization of the pre-initiation complex, which 
is essential for transcription initiation (Chen et al. 2012; 
Hantsche and Cramer 2017). The core function of Media-
tor is to transmit signals from various transcription factors 
to RNA polymerase II (Pol II) (Allen and Taatjes 2015). 
Binding of the CDK8-module to Mediator has been reported 
to prevent the association of Mediator with the Pol II pre-
initiation complex, thus preventing transcription initiation 
and/or re-initiation. In this way, the CDK8-module is consid-
ered a key molecular switch in Pol II mediated transcription 
(Knuesel et al. 2009). MED13, as well as the other subunits 
of the CDK8-module, are known to be critical regulators 
of developmental gene expression programs in Drosophila, 
zebrafish and C. elegans (Carrera et al. 2008; Poss et al. 
2013). MED13, or its paralog MED13L, forms a direct 
connection of the CDK8 module with the core Mediator 
Fig. 3  Location of missense mutations and in-frame deletion in three-
dimensional structure of MED13 and conservation of affected amino 
acids. A full model of MED13 protein created with I-TASSER mod-
eling was combined with 152 species sequences for MED13 using 
ConSurf mapping. Amino acid coloring is as followed: gray = not 
conserved, yellow = conserved hydrophobic, green = conserved 
hydrophilic, red = conserved polar acidic, blue = conserved polar 
basic, magenta = conserved human variants of interest. A zoomed 
in view of the three different affected regions are shown, along with 
amino acid alignments from MED13 and MED13L. An asterisk (*) 
indicates 100% conservation in all sequences and a colon (:) indicates 
functional conservation. Linear motifs mapped with the Eukaryotic 
Linear Motif tool are shown below sites for 326–327 and 540
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complex (Daniels 2013), and protein turnover of MED13 
(or MED13L) may be critical in modulating the pools of 
Mediator-CDK8 kinase complex in cells (Davis et al. 2013; 
Knuesel et al. 2009; Tsai et al. 2013).
Three missense mutations (p.Thr326Ile, p.Pro327Ser and 
p.Pro327Gln) and one in-frame-deletion (p.Thr326del) in 
our cohort are likely to affect MED13 protein turnover due to 
their location within a conserved phosphodegron. This phos-
phodegron is recognized by the SCF-Fbw7 ubiquitin ligase, 
which targets the MED13 protein for ubiquitination and 
degradation (Davis et al. 2013). In fact, it has already been 
shown that a specific amino acid substitution at position 326 
in MED13 (p.Thr326Ala) leads to impaired binding of Fbw7 
to the phosphodegron of MED13/MED13L, thus prevent-
ing MED13/MED13L ubiquitination and degradation (Davis 
et al. 2013). Therefore, a variant at this position may lead to 
increased levels of MED13 protein in the cell. As Fbw7 is 
proposed to target only MED13 or MED13L proteins that 
are bound to the core Mediator complex (Davis et al. 2013), 
Fig. 4  Analysis of transcript and protein levels in patient with non-
sense mutation. a Level of MED13 transcript was measured by qPCR 
and normalized to GAPDH and proband (patient J). No differences 
were detectable between groups (One-way ANOVA p = 0.5913). An 
additional loading control (AGPAT) produced very similar results 
(data not shown). b Representative Sanger traces from cDNA ampli-
cons demonstrating the presence of the variant in the proband, and 
absence in the father and mother. c Quantification of the chromato-
grams of all Sanger sequences reveals less signal from the base on the 
mutant allele (p < 0.0001 by paired t-test compared to the wildtype 
base signal by trace). The father and mother do not have any signal at 
the mutant base above the level of noise. d Western blot for MED13 
(and HSP90 and HDAC2 as loading controls) from nuclear extracts of 
patient peripheral blood mononuclear cells or a neural precursor cell 
line (present to demonstrate antibody specificity with a knockdown 
(KD) control). If the nonsense mutation resulted in a stable protein, 
a product at approximately 150 kDa would be expected, which is not 
present. No protein was recoverable from the blood sample from the 
mother
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these mutations may have an effect on the CDK8 module-
Mediator association and subsequently on transcription reg-
ulation. The potential effects of the p.Pro540Thr missense 
variant are also intriguing. Protein modeling suggests that 
this variant could introduce an additional Casein Kinase 1 
phosphorylation site, thus potentially increasing interactions 
with forkhead-associated domains involved in protein–pro-
tein interactions.
We also observed five unique mutations predicted to trun-
cate MED13. In assessments of RNA and protein levels in 
Patient J and her unaffected parents, the variant transcript 
was detected in the proband but no truncated protein could 
be observed. While these results are inconclusive with 
regards to the molecular mechanism of pathogenicity in 
this particular proband, loss-of-function mechanisms remain 
an attractive possibility. Patterns of variation in MED13 in 
human population databases indicate that MED13 is rela-
tively intolerant to loss-of-function variation; MED13 has a 
Rare Variant Intolerance Score (RVIS) that ranks among the 
top 1.66% of all genes (Petrovski et al. 2013) and an ExAC 
pLI score of 1.00 (Lek et al. 2016).
We show an enrichment of de novo MED13 muta-
tions compared to what is expected under a null model 
(p = 0.00371) in two large ID/DD patient cohorts. We 
acknowledge that this p value does not exceed a genome-
wide evidence threshold and by itself proves association. 
However, the enrichment p value does not account for five 
de novo variants described here from smaller cohorts that 
were discovered independent of, and prior to, assessment 
of the statistical evidence from the larger cohorts. We also 
observed clustering of missense mutations in our cohort, 
which by itself is an argument for pathogenicity (Lelieveld 
et al. 2017). Additionally, independent genetic studies also 
support the disease relevance of variation in MED13. There 
is one report of an 800-kb microdeletion including MED13 
and five other genes in a patient with moderate ID, short 
stature, mild dysmorphisms, and hearing loss (Boutry-Kryza 
et al. 2012); the authors proposed MED13 as the most likely 
causal candidate gene. Additionally, a de novo frameshift 
(p.Pro286Leufs*86) and a de novo variant that likely affects 
splicing (D + 3; c.814+3A>G) were observed in a cohort of 
2508 probands with ASD (Iossifov et al. 2014), and three 
rare protein-altering variants in MED13 (p.Ala418Thr, 
p.Arg512*, p.Tyr1649*) were also found in a separate ASD 
cohort (Yuen et al. 2017).
Other Mediator subunits, including other CDK8-kinase 
module-associated disease genes, have been associated with 
various neurodevelopmental disorders. Variants in MED12 
have been associated with ID syndromes with congenital 
abnormalities, including Opitz-Kaveggia syndrome (MIM 
305,450) (Risheg et al. 2007), Lujan-Fryns syndrome (MIM 
309,520) (Schwartz et al. 2007) and X-linked Ohdo syn-
drome (MIM 300,896) (Vulto-van Silfhout et al. 2013). 
Mutations in MED12 have also been associated with intel-
lectual disability. In addition to ID and speech delays both 
MED12 patients and several MED13 probands described 
here present with eye abnormalities (eye movement dis-
orders, and abnormalities of the retina and optic nerves) 
(Clark et al. 2009; Donnio et al. 2017) and chronic obstipa-
tion (Donnio et al. 2017; Lyons 1993). In addition to the 
MED12 subunit, a disruption of CDK19 was reported in a 
patient with ID, microcephaly and congenital retinal folds 
(Mukhopadhyay et al. 2010).
It is of particular relevance to this study that variation 
in the MED13-paralog MED13L has been shown to cause 
a neurodevelopmental disorder as well (Asadollahi et al. 
2013). Given the similar molecular roles for MED13 and 
MED13L, we aimed to compare and contrast phenotypes 
presented by both groups of individuals using information 
provided in the literature. The main phenotypic character-
istics of MED13L-associated syndrome are (borderline) ID 
with delayed speech and language development, and a vari-
able spectrum of other features including autism, hypotonia, 
characteristic facial features and heart defects (Adegbola 
et al. 2015; Caro-Llopis et al. 2016; Martinez et al. 2017; 
Muncke et al. 2003; van Haelst et al. 2015). Many of these 
features clearly overlap with the phenotypes in our MED13 
cohort. However, similar to the heterogeneity observed 
here in patients with MED13 variation, the spectrum of 
phenotypes observed among MED13L mutation carriers is 
quite broad. The identification and detailed phenotyping of 
additional patients with MED13 and MED13L mutations is 
needed to elucidate the complete spectrum of associated fea-
tures, and to reveal the similarities and differences between 
the two syndromes.
We believe that the data presented in this study cou-
pled to the additional evidence available from other studies 
strongly support the conclusion that rare protein-altering 
variation in MED13 underlie a new neurodevelopmental 
disorder. Key results from this study include: a significant 
enrichment of de novo mutations in MED13 within ID/DD 
cohorts (p = 0.00371); the clustering and conservation levels 
of the positions affected by the observed missense variation 
(Fig. 2a, b); the computationally predicted deleteriousness 
of the observed mutations (Table 1; Fig. 3, Supplementary 
Fig. 1); and the overlap of phenotypic features among the 13 
patients presented here, including speech difficulties (13/13), 
intellectual disability (at least 9/13), and eye or vision prob-
lems (8/13). Supporting evidence from other studies include: 
the existence of mutations affecting MED13 in at least six 
independent families affected by pediatric neurodevelop-
mental disorders; the intolerance of MED13 to mutations 
in the general human population (pLI = 1.00, RVIS score of 
1.66%); and the previously established disease-associations 
of several other Mediator subunits, including MED13L, a 
functionally related paralog of MED13. While the precise 
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pathogenic mechanisms have yet to be elucidated—some 
of the mutations observed here are predicted to stabilize 
MED13 protein while others are predicted to lead to loss-of-
function—we find it highly likely that mutational disruption 
of normal MED13 function leads to disease, adding MED13 
to the list of Mediator-associated, in particular CDK8-kinase 
module-associated, neurodevelopmental disorders.
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